Search

Your search keyword '"Chang Fang"' showing total 633 results

Search Constraints

Start Over You searched for: Author "Chang Fang" Remove constraint Author: "Chang Fang" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
633 results on '"Chang Fang"'

Search Results

1. Take You Back to Hometown: Does Food Awaken Memories of 'Place'? — Analysis Based on Disembedding Mechanism and Media Geography

2. The Effect of Heat Stress on Sensory Properties of Fresh Oysters: A Comprehensive Study Using E-Nose, E-Tongue, Sensory Evaluation, HS–SPME–GC–MS, LC–MS, and Transcriptomics

3. Sex-dependent differences in the genomic profile of lingual sensory neurons in naïve and tongue-tumor bearing mice

4. Gender Impacted Gut Microbiota and Growth Performance in the Blotched Snakehead (Channa maculata)

5. An Experimental Study and Numerical Simulation Analysis of Thermal Oxidation Characteristics Based on Kinetic Parameters in Heavy Oil Reservoirs

6. A retrospective analysis for the management of oromaxillofacial invasive mucormycosis and systematic literature review

7. Occupational exposure in swine farm defines human skin and nasal microbiota

8. Urbanization alters soil bacterial communities in southern China coastal cities

9. Mortality burden due to long-term exposure to ambient PM2.5 above the new WHO air quality guideline based on 296 cities in China

10. Consumer perception of 'Green' and Sustainable Development Goals (the case of fashion product design and charm attributes)

19. Safety analysis by treatment periods from EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma.

37. Cognitive Ability and Academic Performance among Left-Behind Children: Evidence from Rural China

38. Feeling Bad and Doing Bad: Student Confidence in Reading in Rural China

49. Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.

50. Livmoniplimab with or without budigalimab in patients with advanced solid tumors: Results from the combination therapy in the urothelial carcinoma dose expansion cohort.

Catalog

Books, media, physical & digital resources